Research Article
Activation of Melanocortin Receptors MC1 and MC5 Attenuates Retinal Damage in Experimental Diabetic Retinopathy
Figure 7
Representative immunohistochemistry after 16 weeks of diabetes for ki-67 in the retina of nondiabetic mice (nondiabetic), STZ-diabetic mice with retinopathy (diabetic) after intravitreal treatment or not with MC1 receptor agonist BMS-470539; MC3-MC4 melanocortin receptor agonist MTII; MC1 receptor antagonist agouti related protein (AGRP); MC5 melanocortin receptor agonist PG-901; MC3-MC4 melanocortin receptor antagonist SHU9119; MC5 melanocortin receptor antagonist PG20N. Percentage of positive stained area/total area with significant differences against nondiabetic mice is expressed as . Significant differences versus diabetic are expressed as . R = retina; arrows indicate the positive immunostaining.